Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

Area of Science:

• Hepatology
• Gastroenterology
• Diagnostic Accuracy

Background:

• Accurate assessment of liver fibrosis is crucial for managing non-alcoholic fatty liver disease (NAFLD) and preventing complications.
• Identifying patients with advanced fibrosis aids in stratifying risk and guiding treatment decisions.

Purpose of the Study:

• To compare the diagnostic performance of non-invasive tests for identifying advanced liver fibrosis in biopsy-proven NAFLD patients.
• To evaluate the utility of simple blood tests in excluding advanced fibrosis.

Main Methods:

• Retrospective analysis of 145 biopsy-proven NAFLD patients from 2003-2009.
• Calculation of AST/ALT ratio, AST to platelet ratio index, BARD score, FIB-4 score, and NAFLD fibrosis score from blood tests.
• Comparison of diagnostic accuracy (AUROC) and predictive values for advanced fibrosis.

Main Results:

• FIB-4 score demonstrated the highest diagnostic accuracy (AUROC 0.86) for advanced fibrosis, followed by AST/ALT ratio (0.83) and NAFLD fibrosis score (0.81).
• AST/ALT ratio, BARD score, FIB-4, and NAFLD fibrosis scores showed high negative predictive values (>90%), enabling exclusion of advanced fibrosis.
• Liver biopsy could potentially be avoided in a significant proportion of patients (up to 69% with AST/ALT ratio).

Conclusions:

• AST/ALT ratio, FIB-4, and NAFLD fibrosis scores reliably exclude advanced fibrosis in a substantial number of NAFLD patients.
• These non-invasive tests can help direct liver biopsy use more effectively.
• Simple blood tests offer a valuable tool for managing NAFLD fibrosis assessment.